[Federal Register Volume 85, Number 134 (Monday, July 13, 2020)]
[Notices]
[Pages 41989-41990]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14998]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2019-D-0358]
Cancer Clinical Trial Eligibility Criteria: Minimum Age
Considerations for Inclusion of Pediatric Patients; Guidance for
Industry and Institutional Review Boards; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a final guidance for industry and institutional
review boards (IRBs) entitled ``Cancer Clinical Trial Eligibility
Criteria: Minimum Age Considerations for Inclusion of Pediatric
Patients.'' This guidance is one in a series of guidances that provide
recommendations regarding eligibility criteria for clinical trials of
drugs or biological products regulated by the Center for Drug
Evaluation and Research (CDER) and the Center for Biologics Evaluation
and Research (CBER) for the treatment of cancer. Specifically, this
guidance includes recommendations on the inclusion of pediatric
patients (i.e., children and adolescents) in clinical trials for cancer
treatments. This guidance finalizes the draft guidance entitled
``Cancer Clinical Trial Eligibility Criteria: Minimum Age for Pediatric
Patients'' that published on March 13, 2019.
DATES: The announcement of the guidance is published in the Federal
Register on July 13, 2020.
ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2019-D-0358 for ``Cancer Clinical Trial Eligibility Criteria:
Minimum Age Considerations for Inclusion of Pediatric Patients.''
Received comments will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single copies of this guidance to the
Division of Drug Information, Center for Drug Evaluation and Research,
Food and Drug Administration, 10001 New Hampshire Ave., Hillandale
Building, 4th Floor, Silver Spring, MD 20993-0002; or to the Office of
Communication, Outreach and Development, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the guidance document.
FOR FURTHER INFORMATION CONTACT: Julia Beaver, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 2100, Silver Spring, MD 20993-0002, 240-
402-0489; or Stephen Ripley, Center for Biologics Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a guidance for industry and
IRBs entitled ``Cancer Clinical Trial Eligibility Criteria: Minimum Age
Considerations for Inclusion of Pediatric Patients.'' This guidance
provides
[[Page 41990]]
recommendations on the inclusion of pediatric patients in clinical
trials of drugs or biological products regulated by CDER and CBER for
the treatment of cancer.
A clinical trial's eligibility criteria (for inclusion and
exclusion) are essential components of the trial, defining the
characteristics of the study population. Because there is variability
in investigational drugs and trial objectives, eligibility criteria
should be developed, taking into consideration the mechanism of action
of the drug, the targeted disease or patient population, the
anticipated safety of the investigational drug, the availability of
adequate safety data, and the ability to recruit trial participants
from the patient population to meet the objectives of the clinical
trial. However, some eligibility criteria have become commonly accepted
over time or used as a template across trials without clear scientific
or clinical rationale. Unnecessarily restrictive eligibility criteria
may slow patient accrual, limit patients' access to clinical trials,
and lead to trial results that do not fully represent treatment effects
in the patient population that will ultimately use the drug. Broadening
cancer trial eligibility criteria can maximize the generalizability of
trial results and the ability to understand the therapy's benefit-risk
profile across the patient population likely to use the drug in
clinical practice and should be considered to avoid jeopardizing
patient safety. Early evaluation and development of potentially
effective drugs, particularly targeted drugs, in pediatric patients may
provide information on safe and effective use, therefore reducing risks
associated with off label use, and accelerate the development of
effective, innovative therapies for pediatric patients.
The guidance includes recommendations regarding minimum age
eligibility criteria and addresses specific situations in which the
inclusion of children (for the purposes of this guidance, ages 2 years
to younger than 12 years) and adolescents (for the purposes of this
guidance, ages 12 years to 17 years) is appropriate in cancer trials
(i.e., based on disease biology and clinical course, molecular target
of the investigational drug, and/or its molecular mechanism). In
addition, the guidance includes ethical and regulatory considerations
for including pediatric patients in such trials.
In the Federal Register of March 13, 2019 (84 FR 9130), FDA
announced the availability of the draft guidance entitled ``Cancer
Clinical Trial Eligibility Criteria: Minimum Age for Pediatric
Patients.'' FDA received comments and considered those comments as the
guidance was finalized. The final guidance recommends specific issues
to discuss with FDA and provides additional recommendations for
providing care in pediatric oncology trials. In addition, the final
guidance includes additional information for clarification, for example
regarding types of evidence that could support inclusion of children
and dosing considerations in early phase trials.
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
current thinking of FDA on ``Cancer Clinical Trial Eligibility
Criteria: Minimum Age Considerations for Inclusion of Pediatric
Patients.'' It does not establish any rights for any person and is not
binding on FDA or the public. You can use an alternative approach if it
satisfies the requirements of the applicable statutes and regulations.
II. Paperwork Reduction Act of 1995
This guidance refers to previously approved FDA collections of
information. These collections of information are subject to review by
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501-3521). The collections of information in 21
CFR part 312 have been approved under OMB control number 0910-0014; the
collections of information in 21 CFR 201.56 and 201.57 have been
approved under OMB control number 0910-0572.
III. Electronic Access
Persons with access to the internet may obtain the guidance at
either https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances, or https://www.regulations.gov.
Dated: July 7, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-14998 Filed 7-10-20; 8:45 am]
BILLING CODE 4164-01-P